Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 4, 2007, Pages 290-295

  Okuyama, Cristina E ^a   Mendes, Gustavo Duarte ^a   Faro, Renato ^a   Rezende, Vinicius M ^a,b   Lagos, Rodolfo Monaco ^a   Astigarraga, Rafael E B ^a,b   Antunes, Edson ^a   De Nucci, Gilberto ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin converting enzyme; Hypertension; Nitro enalapril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; N [1 (ETHOXYCARBONYL) 3 PHENYLPROPYL]ALANYLPROLINE 3 NITROOXYPROPYL ESTER MALEATE; NCX 899; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; ENZYME ACTIVITY; HYPERTENSION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AREA UNDER CURVE; BLOOD PRESSURE; CHROMATOGRAPHY, LIQUID; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; ENALAPRILAT; ENZYME INHIBITORS; HALF-LIFE; HEART RATE; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; MALE; MOLECULAR STRUCTURE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE DONORS; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 33846977745     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04559.x     Document Type: Article

References (36)

1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 1991; 43: 109-42.
2. Hussain SNA. Activity of nitric oxide synthase in the ventilatory muscle vasculature. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 1998; 119: 191-201.
3. Higashi Y, Chayama K. Renal endothelial dysfunction and hypertension. J. Diabetes Complications 2002; 16: 103-7.
4. Ribeiro MO, Antunes E, De Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992; 20: 298-303.
5. Moreno H, Metze K, Bento AC, Antunes E, Zatz R, De Nucci G. Chronic nitric oxide inhibition as a model of hypertension heart muscle disease. Basic Res. Cardiol. 1996; 91: 248-55.
6. Wallace JL, Reuter BK, Cirino G. Nitric oxide-releasing non-steroidal anti-inflammatory drugs: A novel approach for reducing gastrointestinal toxicity. J. Gastroenterol. Hepatol. 1994; 9 (Suppl. 1): S40-4.
7. Burgaud JL, Ongini E, Del Soldato P. Nitric oxide-releasing drugs: A novel class of effective and safe therapeutic agents. Ann. N.Y. Acad. Sci. 2002; 962: 360-71.
8. Napoli C, Ignarro LJ. Nitric oxide-releasing drugs. Annu. Rev. Pharmacol. Toxicol. 2003; 43: 97-123.
9. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994; 107: 173-9.
10. al-Swayeh OA, Futter LE, Clifford RH, Moore PK. Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity. Br. J. Pharmacol. 2000; 130: 1453-6.
11. Muscará MN, McKnight W, Lovren F, Triggle CR, Cirino G, Wallace JL. Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am. J. Physiol. Heart Circ. Physiol. 2000; 279: H528-35.
12. Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of nitric oxide-releasing aspirin. Nat. Rev. 2002; 1: 375-82.
13. Nesbit WS, Levagood FB. Preliminary observations on a clinical evaluation of angiotensin II, a new pressor agent. Grace Hosp. Bull. 1961; 39: 9-12.
14. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiol. Res. 2002; 53: 672-7.
15. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor 'MK-421'. Lancet 1981; 12: 543-7.
16. Ferguson RK, Vlasses PH, Swanson BN et al. Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clin. Pharmacol. Ther. 1982; 32: 48-53.
17. Tabacova SA, Kimmel CA. Enalapril: Pharmacokinetic/dynamic inferences for comparative developmental toxicity. Reprod. Toxicol. 2001; 15: 467-78.
18. MacGregor GA, Markandu ND, Bayliss J, Roulston JE, Squires M, Morton JJ. Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): Evidence for role of renin system in normotensive subjects. BMJ 1981; 283: 401-3.
19. Tood PA, Heel RC. Enalapril: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198-248.
20. Shaffer JE, Lee F, Thomson S, Han BJ, Cooke JP, Loscalzo J. The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. J. Pharmacol. Exp. Ther. 1991; 256: 704-9.
21. Tsui DYY, Gambino A, Wanstall JC. S-Nitrosocaptopril: In vitro characterization of pulmonary vascular effects in rats. Br. J. Pharmacol. 2003; 138: 855-64.
22. Iwanaga Y, Gu Y, Dieterle T et al. A nitric oxide-releasing derivate of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamster with heart failure. FASEB J. 2004; 18: 587-8.
23. Najib NM, Idkaidek N, Adel A et al. Bioequivalence evaluation of two brands of enalapril 20 mg tablets (Narapril and Renitec) in healthy human volunteers. Biopharm. Drug Dispos. 2003; 24: 315-20.
24. Araujo MC, Melo RL, Cesari MH, Juliano MA, Juliano L, Carmona AK. Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry 2000; 39: 8519-25.
25. Zappellini A, Teixeira SA, Muscara MN, Zatz R, Antunes E, De Nucci G. In vivo inhibition of nitric oxide synthesis does not depend on renin-angiotensin system activation. Eur. J. Pharmacol. 1996; 317: 285-91.
26. Zappellini A, Moreno Jr H, Antunes E, De Nucci G. Dissociation between the increase in systemic vascular resistance induced by acute nitric oxide synthesis inhibition and the decrease in cardiac output in anesthetised dogs. J. Cardiovasc. Pharmacol. 1997; 29: 45-8.
27. Faro R, Tanus-Santos JE, Zappellini A, Antunes E, De Nucci G. The role of heart rate in the modulation of the decreased cardiac output induced by acute nitric oxide inhibition in anaesthetized dogs. J. Auton. Pharmacol. 1999; 19: 257-62.
28. Ribeiro W, Muscará MN, Martins AR, Moreno HJ, Mendes GB, De Nucci G. Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Eur. J. Clin. Pharmacol. 1996; 50: 399-405.
29. Yamanaka K, Takehara N, Murata K, Banno K, Sato T. Pharmacokinetic and pharmacodynamic study of imidaprilat, an active metabolite of imidapril, a new angiotensin-converting enzyme inhibitor, in spontaneously hypertensive rats. J. Pharm. Biomed. Anal. 1997; 15: 1851-9.
30. Hidaka H, Sawada S, Sato R, Oka H, Yasuda Y. Pharmacological comparison of captopril and MK-422 by a new method for measuring activity of angiotensin converting enzyme (ACE). Jpn. Circ. J. 1985; 49: 1175-9.
31. Ajayi AA, Elliott HL, Reid JL. The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension. Br. J. Clin. Pharmacol. 1986; 22: 167-75.
32. Moncada S, Higgs GA. Leukotrienes in disease. Implications for drug development. Drugs 1993; 30: 1-5.
33. G-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br. J. Pharmacol. 1990; 101: 625-31.
34. G-Nitro- L-arginine methyl ester: Systemic and pulmonary haemodynamics, tissue blood flow and arteriovenous shunting in the pig. Naunyn Schmiedebergs Arch. Pharmacol. 1993; 348: 417-23.
35. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89: 2035-40.
36. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 1998; 32: 958-64.